Skip to main content
. 2021 Jul 28;12:4584. doi: 10.1038/s41467-021-24817-y

Fig. 5. IFITM blocking antibodies and IFITM derived peptides target the N-terminal domain.

Fig. 5

a Alignment of the amino acid sequence of human IFITM1, 2, and 3. Binding sites of IFITM blocking antibodies are indicated and the region of origin of the IFITM derived peptides highlighted. b Quantification of viral N RNA levels in the supernatant of Calu-3 cells treated with α-ACE2, α-IFITM1, α-IFITM2, α-IFITM3, and α-IFITM1-3 antibodies (7.5, 15, or 30 µg/ml) 1 h before infection (SARS-CoV-2, MOI 0.05), collected 48 h post-infection. Bars represent the mean of two (30 µg/ml α-IFITM2) or three (all other concentrations) independent experiments each measured in technical duplicates (±SEM), unpaired t-test. All p values were calculated compared to CTRL (ACE2, 15 µg/ml: 0.0011, ACE2, 30 µg/ml: <0.00001; IFITM2, 30 µg/ml: <0.00001; IFITM1-3, 15 µg/ml: 0.004; IFITM1-3, 30 µg/ml: <0.00001). c Quantification of viral N RNA levels in the supernatant of Calu-3 cells treated with IFITM-derived peptides (20 or 80 µg/ml) as indicated for 1 h before infection (MOI 0.05), collected 48 h post-infection. Bars represent the mean of three (hIFITM2 long and short peptide) or four (CTRL, hIFITM3 and scrambled) independent experiments each measured in technical duplicates (±SEM), unpaired t test. All p values were calculated compared to CTRL (hIFITM2 long, 20 µg/ml: 0.005; hIFITM2 long, 80 µg/ml: <0.0001; hIFITM2 short, 20 µg/ml: 0.0009; hIFITM2 short, 80 µg/ml: 0.0002; hIFITM3, 20 µg/ml: 0.0031). p Values are indicated as *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 or were not significant (p > 0.05).